These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34532493)

  • 1. Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report.
    Xie N; Liu L; Tian C; Hu Z; Ouyang Q
    Ann Transl Med; 2021 Aug; 9(16):1356. PubMed ID: 34532493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.
    Li J; Shui Z; Ouyang Q
    Ann Palliat Med; 2021 Sep; 10(9):10124-10129. PubMed ID: 34628933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.
    Hu ZY; Yan M; Xiong H; Ran L; Zhong J; Luo T; Sun T; Xie N; Liu L; Yang X; Xiao H; Li J; Liu B; Ouyang Q
    BMC Med; 2023 Jun; 21(1):226. PubMed ID: 37365596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study.
    Zhang J; Meng Y; Wang B; Wang L; Cao J; Tao Z; Li T; Yao W; Hu X
    Front Oncol; 2022; 12():775081. PubMed ID: 35321427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
    Wang C; Lin Y; Zhou Y; Mao F; Zhu H; Guan J; Zhang X; Shen S; Huang X; Chen C; Yao R; Zhao J; Sun Q
    BMC Cancer; 2020 Jul; 20(1):653. PubMed ID: 32660609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
    Li Y; Qiu Y; Li H; Luo T; Li W; Wang H; Shao B; Wang B; Ge R
    Front Oncol; 2021; 11():664429. PubMed ID: 33996589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer.
    Yang C; Shangguan C; Lou G; Qu Q
    Ann Palliat Med; 2022 Jan; 11(1):332-338. PubMed ID: 35144424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits.
    Wang H; Liu Q; Zhang M; Zhang J; Ran R; Ma Y; Yang J; Wang F; He S; Zhao X; Wang L; Zhang L; Dong D; Yang J
    Front Oncol; 2023; 13():1105474. PubMed ID: 37397372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report.
    He L; Zhang F; Ma Y; Zuo L; Xu Y
    Onco Targets Ther; 2020; 13():8749-8756. PubMed ID: 32943881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study.
    Zhang Q; He P; Tian T; Yan X; Huang J; Zhang Z; Zheng H; Zhong X; Luo T
    Front Pharmacol; 2023; 14():1100556. PubMed ID: 37025489
    [No Abstract]   [Full Text] [Related]  

  • 14. Individualize management for advanced breast cancer with pyrotinib-based anti-HER2 therapy: a case report.
    Xu J; Chen J; Huang P; Zhou H; Wang X; Chen Z
    Transl Breast Cancer Res; 2023; 4():25. PubMed ID: 38751473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
    Zhu W; Wu J; Cui M; Zhang L
    Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.
    Chen Q; Ouyang D; Anwar M; Xie N; Wang S; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W; Ouyang Q
    Front Oncol; 2020; 10():811. PubMed ID: 32528890
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.
    Gu Q; Zhu M; Wang Y; Gu Y
    Breast Cancer (Dove Med Press); 2024; 16():253-268. PubMed ID: 38812479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies.
    Guan X; Ma F; Li Q; Chen S; Lan B; Fan Y; Wang J; Luo Y; Cai R; Zhang P; Li Q; Xu B
    Biomark Res; 2023 Feb; 11(1):21. PubMed ID: 36803645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis.
    Hu W; Yang J; Zhang Z; Xu D; Li N
    Transl Cancer Res; 2023 Feb; 12(2):247-256. PubMed ID: 36915587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.